Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies

被引：2
|
作者：
Niscola, Pasquale [1 ]
Gianfelici, Valentina [1 ]
Catalano, Gianfranco [2 ]
Giovannini, Marco [1 ]
Mazzone, Carla [1 ]
Noguera, Nelida Ines [2 ,3 ]
de Fabritiis, Paolo [1 ,2 ]
机构：
[1] S Eugenio Hosp ASL Roma 2, Hematol Unit, I-00144 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy
[3] IRCCS, St Lucia Fdn, Neurooncoemtol Units, I-00143 Rome, Italy
来源：
CURRENT ONCOLOGY | 2024年 / 31卷 / 11期
关键词：
genomic profiling; targeted therapies; hypomethylating agents; venetoclax-based combinations; intensive chemotherapy; transplantation clinical trials; supportive care; quality of life; HEALTH-ORGANIZATION CLASSIFICATION; MEASURABLE RESIDUAL DISEASE; VENETOCLAX-BASED THERAPY; GILTERITINIB; AZACITIDINE; METABOLISM; CHEMOTHERAPY; NEOPLASMS; EVOLUTION; CRITERIA;
D O I：
10.3390/curroncol31110490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, and suitability for induction intensive chemotherapy and allogenic stem cells transplantation. Recent research into the molecular and biological factors contributing to disease development and progression has led to significant advancements in treatment approaches for older patients with AML. This review article discusses the latest biological and therapeutic developments that are transforming the management of AML in older adults.
引用
收藏
页码：6632 / 6658
页数：27
相关论文
共 50 条
  • [1] Targeted therapies and autophagy New insights from chronic myeloid leukemia
    Salomoni, Paolo
    Calabretta, Bruno
    AUTOPHAGY, 2009, 5 (07) : 1050 - 1051
  • [2] New agents for acute myeloid leukemia: is it time for targeted therapies?
    Ferrara, Felicetto
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 179 - 189
  • [3] Resistance to targeted therapies in acute myeloid leukemia
    Mecklenbrauck, Rabea
    Heuser, Michael
    CLINICAL & EXPERIMENTAL METASTASIS, 2023, 40 (01) : 33 - 44
  • [4] Molecularly targeted therapies for acute myeloid leukemia
    Stein, Eytan M.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 579 - 583
  • [5] An Overview of Targeted Therapies in Acute Myeloid Leukemia
    Turkalj, Sven
    Radtke, Felix A.
    Vyas, Paresh
    HEMASPHERE, 2023, 7 (06): : E914
  • [6] Resistance to targeted therapies in acute myeloid leukemia
    Rabea Mecklenbrauck
    Michael Heuser
    Clinical & Experimental Metastasis, 2023, 40 : 33 - 44
  • [7] New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
    Chen, Jing
    Glasser, Chana L.
    CHILDREN-BASEL, 2020, 7 (02):
  • [8] Non-intensive acute myeloid leukemia therapies for older patients
    Babakhanlou, Rodrick
    Ravandi-Kashani, Farhad
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (03) : 171 - 180
  • [9] Acute Myeloid Leukemia: From Molecular Pathogenesis to Oral Targeted Therapies
    Chung, Clement
    US PHARMACIST, 2019, 44 (05) : 4 - 8
  • [10] Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
    Masetti, Riccardo
    Kleinschmidt, Katharina
    Biagi, Carlotta
    Pession, Andrea
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (03) : 354 - 366
12345